Literature DB >> 26435297

Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed.

Thai P Hong1, Paul Gow2,3, Michael Fink4, Anouk Dev5, Stuart Roberts6, Amanda Nicoll7,8,9, John Lubel7,9, Ian Kronborg10, Niranjan Arachchi10, Marno Ryan1, William Kemp6, Virginia Knight5, Helen Farrugia11, Vicky Thursfield11, Paul Desmond1, Alexander J Thompson1, Sally Bell1.   

Abstract

UNLABELLED: Hepatocellular carcinoma (HCC) incidence is rising rapidly in many developed countries. Primary epidemiological data have invariably been derived from cancer registries that are heterogeneous in data quality and registration methodology; many registries have not adopted current clinical diagnostic criteria for HCC and still rely on histology for classification. We performed the first population-based study in Australia using current diagnostic criteria, hypothesizing that HCC incidence may be higher than reported. Incident cases of HCC (defined by American Association for the Study of Liver Diseases diagnostic criteria or histology) were prospectively identified over a 12-month period (2012-2013) from the population of Melbourne, Australia. Cases were captured from multiple sources: admissions to any of Melbourne's seven tertiary hospitals; attendances at outpatients; and radiology, pathology, and pharmacy services. Our cohort was compared to the Victorian Cancer Registry (VCR) cohort (mandatory notified cases) for the same population and period, and incidence rates were compared for both cohorts. There were 272 incident cases (79% male; median age: 65 years) identified. Cirrhosis was present in 83% of patients, with hepatitis C virus infection (41%), alcohol (39%), and hepatitis B virus infection (22%) the commonest etiologies present. Age-standardized HCC incidence (per 100,000, Australian Standard Population) was 10.3 (95% confidence interval [CI]: 9.0-11.7) for males and 2.3 (95% CI: 1.8 to 3.0) for females. The VCR reported significantly lower rates of HCC: 5.3 (95% CI: 4.4 to 6.4) and 1.0 (95% CI: 0.7 to 1.5) per 100,000 males and females respectively (P < 0.0001).
CONCLUSIONS: HCC incidence in Melbourne is 2-fold higher than reported by cancer registry data owing to under-reporting of clinical diagnoses. Adoption of current diagnostic criteria and additional capture sources will improve registry completeness. Chronic viral hepatitis and alcohol remain leading causes of cirrhosis and HCC.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 26435297     DOI: 10.1002/hep.28267

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

1.  [Expression and clinical significance of chemokine CXCL10 and its receptor CXCR3 in hepatocellular carcinoma].

Authors:  J Zhang; J Chen; G W Guan; T Zhang; F M Lu; X M Chen
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-06-18

2.  Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.

Authors:  Marina Serper; Tamar H Taddei; Rajni Mehta; Kathryn D'Addeo; Feng Dai; Ayse Aytaman; Michelle Baytarian; Rena Fox; Kristel Hunt; David S Goldberg; Adriana Valderrama; David E Kaplan
Journal:  Gastroenterology       Date:  2017-03-07       Impact factor: 22.682

3.  Epidemiology of chronic hepatitis B virus in Ireland using routinely collected surveillance and administrative data, 2004-2014.

Authors:  Caroline E van Gemert; Niamh Murphy; Tara A Mitchell; Margaret E Hellard; Lelia Thornton
Journal:  Ir J Med Sci       Date:  2017-12-09       Impact factor: 1.568

4.  Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study.

Authors:  Mark G Swain; Alnoor Ramji; Keyur Patel; Giada Sebastiani; Abdel Aziz Shaheen; Edward Tam; Paul Marotta; Magdy Elkhashab; Harpreet S Bajaj; Chris Estes; Homie Razavi
Journal:  CMAJ Open       Date:  2020-06-09

Review 5.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

Authors:  Daniel Q Huang; Hashem B El-Serag; Rohit Loomba
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-12-21       Impact factor: 46.802

6.  Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study.

Authors:  Nicola Coppola; Lorenzo Onorato; Valentina Iodice; Mario Starace; Carmine Minichini; Nunzia Farella; Giulia Liorre; Pietro Filippini; Evangelista Sagnelli; Giorgio de Stefano
Journal:  Oncotarget       Date:  2016-09-20

7.  IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.

Authors:  Rui Liu; Chengyong Tang; Ai Shen; Huating Luo; Xufu Wei; Daofeng Zheng; Chao Sun; Zhongtang Li; Di Zhu; Tingting Li; Zhongjun Wu
Journal:  Oncotarget       Date:  2016-12-20

8.  Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology.

Authors:  Chimaobi M Anugwom; Manon Allaire; Sheikh Mohammad Fazle Akbar; Amir Sultan; Steven Bollipo; Angelo Z Mattos; Jose D Debes
Journal:  Hepatoma Res       Date:  2021-03-26

Review 9.  Therapeutic Strategies in HCC: Radiation Modalities.

Authors:  R Gallicchio; A Nardelli; P Mainenti; A Nappi; D Capacchione; V Simeon; C Sirignano; F Abbruzzi; F Barbato; M Landriscina; G Storto
Journal:  Biomed Res Int       Date:  2016-08-03       Impact factor: 3.411

10.  Role of T-Helper 9 Cells in Chronic Hepatitis C-Infected Patients.

Authors:  Mohamed E Ali; Omnia El-Badawy; Noha A Afifi; Abeer Sharaf Eldin; Elham Ahmed Hassan; Hamada M Halby; Mohamed Ahmed El-Mokhtar
Journal:  Viruses       Date:  2018-06-24       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.